A Comparative Bioavailability Study of a Single Dose of Ziltivekimab Formulation B in a Manual Syringe, Formulation D in a Manual Syringe and Formulation C in a Pen-injector
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Ziltivekimab (Primary)
- Indications Cardiovascular disorders; Inflammation; Kidney disorders
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 22 Dec 2023 Planned End Date changed from 8 Jan 2024 to 12 Jan 2024.
- 22 Dec 2023 Planned primary completion date changed from 8 Jan 2024 to 12 Jan 2024.